Market Update: Johnson & Johnson (NYSE:JNJ) – J&J says its diabetes drug should have same survival edge as Lilly’s

[Reuters – UK Focus] – Oct (HKSE: 3366-OL.HK – news) 13 (Reuters) – Johnson & Johnson (NYSE: JNJ – news) said the proven ability of Eli Lilly and Co’s rival Jardiance diabetes drug . . . → Read More: Market Update: Johnson & Johnson (NYSE:JNJ) – J&J says its diabetes drug should have same survival edge as Lilly’s Similar Articles: Company Update (NYSE:LLY): J&J says its diabetes drug should have same survival edge as Lilly’s Market Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Participate in the 2015 Morgan Stanley Healthcare Conference Stock Update: Johnson & Johnson (NYSE:JNJ) – U.S. FDA warns on newer class of type 2 diabetes drugs